Mechanisms of inactivation of E-cadherin in breast cancer cell lines

Shunsuke Hiraguri, Tony Godfrey, Haruhiko Nakamura, Jeremy Graff, Collin Collins, Laleh Shayesteh, Norman Doggett, Keith Johnson, Margaret Wheelock, James Herman, Stephen Baylin, Daniel Pinkel, Joe Gray

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Loss of E-cadherin (CDH1) function is thought to contribute to progression in breast cancer and other solid tumors by increasing proliferation, invasion, and/or metastasis. In some cases, the restoration of CDH1 function may be an important therapeutic option. This possibility will depend on the mechanism by which CDH1 is inactivated. Here we present analyses of CDH1 expression, genetic mutation, and promoter methylation in CDH1 in 10 commonly used breast cancer cell lines. Five cell lines (BT-474, MCF-7, MDA-MB-361, MDA-MB-468, and T-47D) expressed CDH1 and were genetically normal. Five others (SK-BR-3, 600 MPE, MDA-MB-134 IV, CAMA1, and MDA-MB-435) did not express CDH1. Fluorescence in situ hybridization analyses of each of these cell lines showed evidence for the physical deletion of one allele of CDH1, and three cell lines were found to carry homozygous deletions. SK-BR-3 was deleted from exon 12 through the promoter; exon 6 was deleted in MDA-MB- 134 IV cells, and 600 MPE cells carried a 21-bp deletion in the splicing acceptor site for exon 9. CAMA1 seemed to have been inactivated through promoter methylation. No explanation was found for the inactivation of CDH1 in MDA-MB-435.

Original languageEnglish (US)
Pages (from-to)1972-1977
Number of pages6
JournalCancer Research
Volume58
Issue number9
StatePublished - May 1 1998
Externally publishedYes

Fingerprint

Cadherins
Breast Neoplasms
Cell Line
Exons
Methylation
Fluorescence In Situ Hybridization
Genetic Promoter Regions
Alleles
Neoplasm Metastasis
Mutation
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hiraguri, S., Godfrey, T., Nakamura, H., Graff, J., Collins, C., Shayesteh, L., ... Gray, J. (1998). Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Research, 58(9), 1972-1977.

Mechanisms of inactivation of E-cadherin in breast cancer cell lines. / Hiraguri, Shunsuke; Godfrey, Tony; Nakamura, Haruhiko; Graff, Jeremy; Collins, Collin; Shayesteh, Laleh; Doggett, Norman; Johnson, Keith; Wheelock, Margaret; Herman, James; Baylin, Stephen; Pinkel, Daniel; Gray, Joe.

In: Cancer Research, Vol. 58, No. 9, 01.05.1998, p. 1972-1977.

Research output: Contribution to journalArticle

Hiraguri, S, Godfrey, T, Nakamura, H, Graff, J, Collins, C, Shayesteh, L, Doggett, N, Johnson, K, Wheelock, M, Herman, J, Baylin, S, Pinkel, D & Gray, J 1998, 'Mechanisms of inactivation of E-cadherin in breast cancer cell lines', Cancer Research, vol. 58, no. 9, pp. 1972-1977.
Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L et al. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Research. 1998 May 1;58(9):1972-1977.
Hiraguri, Shunsuke ; Godfrey, Tony ; Nakamura, Haruhiko ; Graff, Jeremy ; Collins, Collin ; Shayesteh, Laleh ; Doggett, Norman ; Johnson, Keith ; Wheelock, Margaret ; Herman, James ; Baylin, Stephen ; Pinkel, Daniel ; Gray, Joe. / Mechanisms of inactivation of E-cadherin in breast cancer cell lines. In: Cancer Research. 1998 ; Vol. 58, No. 9. pp. 1972-1977.
@article{d2ce50651484486eb2b984f85d88fcb0,
title = "Mechanisms of inactivation of E-cadherin in breast cancer cell lines",
abstract = "Loss of E-cadherin (CDH1) function is thought to contribute to progression in breast cancer and other solid tumors by increasing proliferation, invasion, and/or metastasis. In some cases, the restoration of CDH1 function may be an important therapeutic option. This possibility will depend on the mechanism by which CDH1 is inactivated. Here we present analyses of CDH1 expression, genetic mutation, and promoter methylation in CDH1 in 10 commonly used breast cancer cell lines. Five cell lines (BT-474, MCF-7, MDA-MB-361, MDA-MB-468, and T-47D) expressed CDH1 and were genetically normal. Five others (SK-BR-3, 600 MPE, MDA-MB-134 IV, CAMA1, and MDA-MB-435) did not express CDH1. Fluorescence in situ hybridization analyses of each of these cell lines showed evidence for the physical deletion of one allele of CDH1, and three cell lines were found to carry homozygous deletions. SK-BR-3 was deleted from exon 12 through the promoter; exon 6 was deleted in MDA-MB- 134 IV cells, and 600 MPE cells carried a 21-bp deletion in the splicing acceptor site for exon 9. CAMA1 seemed to have been inactivated through promoter methylation. No explanation was found for the inactivation of CDH1 in MDA-MB-435.",
author = "Shunsuke Hiraguri and Tony Godfrey and Haruhiko Nakamura and Jeremy Graff and Collin Collins and Laleh Shayesteh and Norman Doggett and Keith Johnson and Margaret Wheelock and James Herman and Stephen Baylin and Daniel Pinkel and Joe Gray",
year = "1998",
month = "5",
day = "1",
language = "English (US)",
volume = "58",
pages = "1972--1977",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Mechanisms of inactivation of E-cadherin in breast cancer cell lines

AU - Hiraguri, Shunsuke

AU - Godfrey, Tony

AU - Nakamura, Haruhiko

AU - Graff, Jeremy

AU - Collins, Collin

AU - Shayesteh, Laleh

AU - Doggett, Norman

AU - Johnson, Keith

AU - Wheelock, Margaret

AU - Herman, James

AU - Baylin, Stephen

AU - Pinkel, Daniel

AU - Gray, Joe

PY - 1998/5/1

Y1 - 1998/5/1

N2 - Loss of E-cadherin (CDH1) function is thought to contribute to progression in breast cancer and other solid tumors by increasing proliferation, invasion, and/or metastasis. In some cases, the restoration of CDH1 function may be an important therapeutic option. This possibility will depend on the mechanism by which CDH1 is inactivated. Here we present analyses of CDH1 expression, genetic mutation, and promoter methylation in CDH1 in 10 commonly used breast cancer cell lines. Five cell lines (BT-474, MCF-7, MDA-MB-361, MDA-MB-468, and T-47D) expressed CDH1 and were genetically normal. Five others (SK-BR-3, 600 MPE, MDA-MB-134 IV, CAMA1, and MDA-MB-435) did not express CDH1. Fluorescence in situ hybridization analyses of each of these cell lines showed evidence for the physical deletion of one allele of CDH1, and three cell lines were found to carry homozygous deletions. SK-BR-3 was deleted from exon 12 through the promoter; exon 6 was deleted in MDA-MB- 134 IV cells, and 600 MPE cells carried a 21-bp deletion in the splicing acceptor site for exon 9. CAMA1 seemed to have been inactivated through promoter methylation. No explanation was found for the inactivation of CDH1 in MDA-MB-435.

AB - Loss of E-cadherin (CDH1) function is thought to contribute to progression in breast cancer and other solid tumors by increasing proliferation, invasion, and/or metastasis. In some cases, the restoration of CDH1 function may be an important therapeutic option. This possibility will depend on the mechanism by which CDH1 is inactivated. Here we present analyses of CDH1 expression, genetic mutation, and promoter methylation in CDH1 in 10 commonly used breast cancer cell lines. Five cell lines (BT-474, MCF-7, MDA-MB-361, MDA-MB-468, and T-47D) expressed CDH1 and were genetically normal. Five others (SK-BR-3, 600 MPE, MDA-MB-134 IV, CAMA1, and MDA-MB-435) did not express CDH1. Fluorescence in situ hybridization analyses of each of these cell lines showed evidence for the physical deletion of one allele of CDH1, and three cell lines were found to carry homozygous deletions. SK-BR-3 was deleted from exon 12 through the promoter; exon 6 was deleted in MDA-MB- 134 IV cells, and 600 MPE cells carried a 21-bp deletion in the splicing acceptor site for exon 9. CAMA1 seemed to have been inactivated through promoter methylation. No explanation was found for the inactivation of CDH1 in MDA-MB-435.

UR - http://www.scopus.com/inward/record.url?scp=0032080669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032080669&partnerID=8YFLogxK

M3 - Article

C2 - 9581841

AN - SCOPUS:0032080669

VL - 58

SP - 1972

EP - 1977

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -